Video pasar

CNBC’s 22 October 2026 transcript reports that Merck and Moderna released full personalized cancer vaccine trial results after a partial social media leak, ahead of a planned Saturday presentation in Madrid. The companies said the vaccine combined with Keytruda cut the risk of melanoma returning or death by 42% versus Keytruda alone, and reduced distant cancer spread or death by 38%. Both stocks were reported lower. The reporter described the findings as positive and suggested elevated expectations could explain the declines. No trade proposal or earlier-trade update was provided.